Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.

Authors
Publication date
20 May 2020
Publisher
'American Society of Clinical Oncology (ASCO)'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Supporting member

      Queen Mary Research Online

      redirect
      oaioai:qmro.qmul.ac.uk:123456789/...
      Last time updated on 03/12/2020
      Supporting member

      Queen Mary Research Online

      redirect
      oaioai:qmro.qmul.ac.uk:123456789/...
      Last time updated on 03/12/2020